5.84  0 (0%)		04-02 16:00
Open: 5.84 High: 5.86 Volume: 751,504		Pre. Close: 5.84 Low: 5.84 Market Cap: 224(M)

Short term
Mid term
Targets	6-month :	6.84	1-year :	7.99
Resists	First :	5.86	Second :	6.84
Pivot price	5.81
Supports	First :	5.77	Second :	5.71
MAs	MA(5) :	5.84	MA(20) :	5.8
	MA(100) :	4.91	MA(250) :	6.81
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	87.2	D(3) :	89.6
RSI	RSI(14): 69.8
52-week	High :	13.84	Low :	3.16

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ NVRO ] has closed below upper band by 25.2%. Bollinger Bands are 88.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 25 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	5.87 - 5.9	5.9 - 5.93
Low:	5.76 - 5.8	5.8 - 5.83
Close:	5.78 - 5.84	5.84 - 5.89

Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.

Thu, 03 Apr 2025
Nevro Corp completes merger with Globus Medical - Investing.com

Thu, 03 Apr 2025
Globus Medical completes acquisition of Nevro Corp. - GlobeNewswire

Thu, 03 Apr 2025
Nevro Corp Completes Merger and Delists from NYSE - TipRanks

Wed, 05 Mar 2025
Nevro Q4 Earnings & Revenues Beat Estimates, Gross Margin Down - Nasdaq

Tue, 04 Mar 2025
Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results - PR Newswire

Tue, 11 Feb 2025
Globus Medical Inks $250M Deal to Acquire Nevro: Stock to Gain? - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NYSE
Sector: Healthcare
Industry: Medical - Devices
Shares Out	38 (M)
Shares Float	34 (M)
Held by Insiders	2.8 (%)
Held by Institutions	110.5 (%)
Shares Short	1,690 (K)
Shares Short P.Month	1,990 (K)

EPS	-3.06
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	6.11
Profit Margin	-27.8 %
Operating Margin	-21.8 %
Return on Assets (ttm)	-10 %
Return on Equity (ttm)	-43.3 %
Qtrly Rev. Growth	-9.2 %
Gross Profit (p.s.)	7.02
Sales Per Share	10.64
EBITDA (p.s.)	-2.19
Qtrly Earnings Growth	0 %
Operating Cash Flow	-19 (M)
Levered Free Cash Flow	-5 (M)

PE Ratio	-1.91
PEG Ratio	0
Price to Book value	0.95
Price to Sales	0.54
Price to Cash Flow	-11.53

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.